Filing Flows › Celularity (CELU) › Q1 2026 › vs Q4 2025
Celularity (CELU) Q1 2026 vs Q4 2025 (quarter over quarter)
Celularity's revenue fell $258K (-6%) from $4.1M in Q4 2025 to $3.8M in Q1 2026. The biggest changes: License Royalty and Other −$189K (-10%); Service −$51K (-4%); Product −$18K (-2%).
Celularity, Q1 2026: revenue $3.8M (-66% year over year), operating margin -263.5%, net earnings $874K, operating cash flow $1.4M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| License Royalty and Other | $1.7M | $1.9M | −$189K | -10% |
| Service | $1.2M | $1.3M | −$51K | -4% |
| Product | $866K | $884K | −$18K | -2% |
| Revenue | $3.8M | $4.1M | −$258K | -6% |
| Other income, net | $11.0M | −$2.3M | $13.3M | — |
| Costs & expenses | $14.9M | $28.5M | −$13.6M | -48% |
| Operating costs | $14.0M | $26.2M | −$12.2M | -47% |
| Net earnings | $874K | −$24.4M | $25.2M | — |
| Cost of revenue | $1.5M | $7.4M | −$5.9M | -80% |
| Research & development | $3.0M | $3.3M | −$353K | -11% |
| SG&A | $9.2M | $15.1M | −$5.9M | -39% |
| Other operating costs | $368K | $377K | −$9K | -2% |
| Operating cash sources | $3.7M | −$19.0M | $22.8M | — |
| Depreciation & amortization | $1.6M | $1.8M | −$206K | -11% |
| Share-based compensation | $1.2M | $3.5M | −$2.3M | -65% |
| Working capital & other | $2.3M | −$13.9M | $16.2M | — |
| Operating cash flow | $1.4M | −$5.1M | $6.5M | — |
Questions
How much did Celularity's revenue grow quarter over quarter in Q1 2026?
Celularity's revenue fell $258K (-6%) from $4.1M in Q4 2025 to $3.8M in Q1 2026.
What drove Celularity's revenue change in Q1 2026?
License Royalty and Other −$189K (-10%); Service −$51K (-4%); Product −$18K (-2%).